ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
Arbutus Biopharma Corporation

Arbutus Biopharma Corporation (ABUS)

2.60
0.11
(4.42%)
Closed March 27 04:00PM
2.60
0.00
( 0.00% )
Pre Market: 07:22AM

Get an advanced news scanner tailored to your needs by ADVFN

Enhance your trading experience

ABUS News

Official News Only

ABUS Discussion

View Posts
db7 db7 2 weeks ago
https://dailycaller.com/2024/03/14/drew-johnson-moderna-covid-vax-patent-infringement-biden-admin/
👍️ 1
Desert dweller Desert dweller 1 month ago
My bad on post a few weeks ago. When I posted about $MRNA cash position, I didn't do the research I should have done and used what was on cash flow statement and didn't look into long term investments, very sloppy of me. Sorry about that.

In today's release, they are projecting to use $4.3 billion of their cash plus investments during 2024. At 12/31/23 they reported cash plus LT investments of $13.3 billion and project about $9 billion at end of 2024. It will take longer than I thought for them to run out of cash and hopefully $ABUS takes a huge chunk of it. Today MRNA had a surprise profit, and I am still hoping that $ABUS finally cleans their clock for their blatant theft of IP.
👍️ 1
Desert dweller Desert dweller 1 month ago
Handle on twitter is @DesertDweller93
๐Ÿ‘๏ธ0
MWM MWM 1 month ago
Great post!

Whatโ€™s your handle on Twitter?
๐Ÿ‘๏ธ0
Desert dweller Desert dweller 2 months ago
I've been saying on X for a month or so that $MRNA will be suffering a drop once it becomes known that they have roughly a year's worth of cash left, I just discovered this recently. They are burning almost $7 billion/year and they will report less than that at 12/31/23. That on top of the fact that during the past 3 years, they spent $7 billion in buybacks at prices much higher than current prices, all the way up to $300+. My prediction is major restructuring or significant secondary very soon. I bet they wish they had that cash now instead of overpriced treasury stock but then mgt wouldn't have been able to sell at those inflated covid prices.

Hope $ABUS puts them into bankruptcy, the f'n thieves and I hope ABUS cleans $PFE and Biontech's clock too. They all know they are stealing the tech and just don't care. About time David kicks Goliath's ass again.
๐Ÿ‘๏ธ0
MWM MWM 2 months ago
A couple bad headlines for MRNA of late. Here is one of todays...

Modernaโ€™s RSV Vaccine May Lose Efficacy Faster Than GSK and Pfizerโ€™s
๐Ÿ‘๏ธ0
db7 db7 2 months ago
yes, quite the drop yesterday and today on mrna... g/l!
๐Ÿ‘๏ธ0
MWM MWM 2 months ago
Puts on $MRNA might be the best play. If they have to pay up to $ABUS I have a feeling it might see a precipitous drop...

MRNA bad news is piling up there...
๐Ÿ‘๏ธ0
db7 db7 2 months ago
https://twitter.com/themightyforego/status/1755757415750865356?s=46
๐Ÿ‘๏ธ0
MWM MWM 2 months ago
And also

Get on Twitter Damn it lol!
๐Ÿ‘๏ธ0
db7 db7 2 months ago
wasn't.. will check it out... thanks!!
๐Ÿ‘๏ธ0
MWM MWM 2 months ago
Also

Are you watching VKTX?
๐Ÿ‘๏ธ0
MWM MWM 2 months ago
Thanks for pointing this out
๐Ÿ‘๏ธ0
db7 db7 2 months ago
interesting (although stock isn't reacting): "Watching Arbutus Biopharma; Hearing Jefferies Issues Note On Arbutus Biopharma On LNP Markman Hearing Saying Judge Favors Company Over Moderna. -BENZINGA"
๐Ÿ‘๏ธ0
db7 db7 2 months ago
"Markman Hearing set for February 8, 2024 โ€“ court will hear arguments on claim construction and expected to issue its order within 60 days of conclusion of the hearing"

from 1/8/2024 Arbutus presentation...
๐Ÿ‘๏ธ0
db7 db7 2 months ago
2,000,000 share block trade woke some people up ...........
๐Ÿ‘๏ธ0
db7 db7 2 months ago
"With respect to the Moderna lawsuit, fact discovery is currently on-going with the claim construction hearing scheduled for February 8, 2024. According to the Court Scheduling Order, which was issued on March 21, 2023, the court is expected to issue its claim construction order within 60 days of conclusion of the claim construction hearing."

https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides
๐Ÿ‘๏ธ0
db7 db7 3 months ago
from what i'm reading, apparently people are not in love with today's update... 1) moderna trial in 2025 when i think it was expected this year and 2) using 'durvalumab' in a trial instead of their own '101' which some say may mean safety signal seen in '101'(?)

all noise to me; markman is why i came here in the first place......

g/l!
๐Ÿ‘๏ธ0
db7 db7 3 months ago
with there being several catalysts, it 'possibly' sets up some safety if only 1 goes bad(?)
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
Iโ€™ll start watching for any unusual options heading into February
๐Ÿ‘๏ธ0
db7 db7 3 months ago
ABUS gets 20% of win and then also owns 12%(?) of Genevant as well...
๐Ÿ‘๏ธ0
db7 db7 3 months ago
ROIV safer for sure but %-wise ABUS would benefit more......
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
$ROIV might be the better play however. Will have to look it up again but I think ROIV would receive the majority of any verdict?
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
No, I myself didnโ€™t realize it. Front screen now, thanks db!

When are you going to set up an account on Twitter!!!
๐Ÿ‘๏ธ0
db7 db7 3 months ago
yep
๐Ÿ‘๏ธ0
db7 db7 3 months ago
correct; pfizer date not yet set 'but' Moderna has... sorry, if I misinterpreted your post...
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
I read this wrong. So there are two trails? One against PFE/BNTX and one against MRNA.
Hmmm
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
A trial date has not been set, but the trial is expected to commence in the first half of 2025. The lawsuit against Pfizer/BioNTech is ongoing and a date for a claim construction hearing has not been set.
๐Ÿ‘๏ธ0
db7 db7 3 months ago
Moderna Claims Construction (ie: Markman hearing) 2/8/2024 with decision expected within 60 days; 'this' should be an event for sure.... positive or negative, we'll have to wait and see- g/l!
๐Ÿ‘๏ธ0
MWM MWM 3 months ago
For now, almost all small biotechs have participated in the melt up to close 2023. We will have to see where 2024 takes us. Their biggest catalyst, the lawsuit with MRNA and BNTX is still a ways away.
But itโ€™s one that is always on my radar.
๐Ÿ‘๏ธ0
db7 db7 3 months ago
going to be a busy 1st half of the year here...
๐Ÿ‘๏ธ0
db7 db7 3 months ago
https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-announces-2024-corporate-objectives-and-provides
๐Ÿ‘๏ธ0
mick mick 3 months ago
https://www.otcmarkets.com/stock/ABUS
๐Ÿ‘๏ธ0
MWM MWM 4 months ago
Iโ€™ll be watching thanks
👍️ 1
db7 db7 4 months ago
ABUS ($1.90) 'might' be time to put this one back on radar? https://stocktwits.com/bs010101/message/552178969
๐Ÿ‘๏ธ0
db7 db7 4 months ago
Thanks Dew!!
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 4 months ago
Lowering HBsAg is the easy part. The question is whether patients who stop treatment will relapse and need to go back on drug; if these patients relapse, then the triple-drug regimen of Imdusiran (AB-729), VTP-300, and a nucleoside is no better than a nucleoside alone.

In other words, itโ€™s too soon to say whether the 3-drug regimen discussed in the ABUS/BRNS* joint PR has any merit.

*f/k/a VACC.
๐Ÿ‘๏ธ0
db7 db7 4 months ago
Hi Dew, your thoughts on the 'Hail Mary' results: https://investor.arbutusbio.com/news-releases/news-release-details/arbutus-biopharma-and-barinthus-bio-present-preliminary-data
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 5 months ago
ABUS pares pipelineโ€”cuts workforce 24%โ€”CEO retires:

https://www.globenewswire.com/news-release/2023/11/07/2774965/14025/en/Arbutus-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Corporate-Update.html

Not naming a new permanent CEO may mean that the company is for sale.
๐Ÿ‘๏ธ0
mick mick 5 months ago
https://www.otcmarkets.com/stock/ABUS
๐Ÿ‘๏ธ0
mick mick 5 months ago
https://www.otcmarkets.com/stock/ABUS
๐Ÿ‘๏ธ0
mick mick 6 months ago
https://www.otcmarkets.com/stock/ABUS
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 7 months ago
ABUS discontinues COVID-therapeutics program:

https://www.globenewswire.com/news-release/2023/09/11/2741168/14025/en/Arbutus-Announces-Pipeline-Updates-and-Dosing-of-the-First-Subject-in-the-Phase-1a-1b-Clinical-Trial-with-AB-101-Cash-Runway-Extended.html The company isโ€ฆ discontinuing its efforts to identify and develop a coronavirus combination therapy that included AB-343, its Mpro candidate, due to an unfavorable PK profile noted in the IND-enabling studies, and a potential nsp12 polymerase inhibitor. ABUS also dropped development of AB-161, an HBV RNA destablizer, due to a safety problem.
๐Ÿ‘๏ธ0
mick mick 7 months ago
ABUS
Arbutus Biopharma Corporation
2.01
-0.05 (-2.43%)
Volume: 410,951
Day Range: 2.00 - 2.07
Last Trade Time: 6:57:07 PM EDT
๐Ÿ‘๏ธ0
DewDiligence DewDiligence 8 months ago
ABUS 2Q23 resultsโ€”COVID phase-1 trial delayed:

https://www.globenewswire.com/news-release/2023/08/03/2717892/14025/en/Arbutus-Reports-Second-Quarter-2023-Financial-Results-and-Corporate-Update.html As of June 30, 2023, we had cash, cash equivalents and investments in marketable securities of $163.5 million compared to $184.3 million as of December 31, 2022. During the six months ended June 30, 2023, we used $46.9 million in operating activities, which was partially offset by $24.6 million of net proceeds from the issuance of common shares under our โ€œat-the-marketโ€ offering program. We expect our 2023 net cash burn to range from between $90 to $95 million, excluding any proceeds received from our โ€œat the market programโ€. The start of a phase-1 trial for AB-343, a SARS-CoV-2 protease inhibitor, has been delayed. Previously, ABUS said phase-1 would start in 3Q23; now, ABUS says IND-enabling studies will be completed in 2H23 (which generally means 4Q23), which probably means the phase-1 start is slated for early 2024.
๐Ÿ‘๏ธ0
mick mick 9 months ago
ABUS
Arbutus Biopharma Corporation
2.22
-0.01 (-0.45%)
Volume: 297,524
Day Range: 2.21 - 2.26
Last Trade Time: 7:20:15 PM EDT
๐Ÿ‘๏ธ0
mick mick 9 months ago
THE LAWYER STUFF
๐Ÿ‘๏ธ0
Paullee Paullee 9 months ago
what was disappointing ?
๐Ÿ‘๏ธ0
mick mick 9 months ago
ABUS
Arbutus Biopharma Corporation
2.41
-0.06 (-2.43%)
Volume: 2,281,991
Day Range: 2.375 - 2.475
Last Trade Time: 6:53:42 PM EDT
๐Ÿ‘๏ธ0
mick mick 9 months ago
DISAPPOINTING ON SUIT $ABUS
๐Ÿ‘๏ธ0

Your Recent History

Delayed Upgrade Clock